|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kudo M: Systemic therapy for
hepatocellular carcinoma: Latest advances. Cancers (Basel).
10:E4122018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li D, Sedano S, Allen R, Gong J, Cho M and
Sharma S: Current treatment landscape for advanced hepatocellular
carcinoma: Patient outcomes and the impact on quality of life.
Cancers (Basel). 11:E8412019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colagrande S, Inghilesi AL, Aburas S,
Taliani GG, Nardi C and Marra F: Challenges of advanced
hepatocellular carcinoma. World J Gastroenterol. 22:7645–7659.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ikeda K: Recent advances in medical
management of hepatocellular carcinoma. Hepatol Res. 49:14–32.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kawaguchi T, Nakano D, Okamura S, Shimose
S, Hayakawa M, Niizeki T, Koga H and Torimura T: Spontaneous
regression of hepatocellular carcinoma with reduction in
angiogenesis-related cytokines after treatment with sodium-glucose
cotransporter 2 inhibitor in a cirrhotic patient with diabetes
mellitus. Hepatol Res. 49:479–486. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shimose S, Tanaka M, Iwamoto H, Niizeki T,
Shirono T, Aino H, Noda Y, Kamachi N, Okamura S, Nakano M, et al:
Prognostic impact of transcatheter arterial chemoembolization
(TACE) combined with radiofrequency ablation in patients with
unresectable hepatocellular carcinoma: Comparison with TACE alone
using decision-tree analysis after propensity score matching.
Hepatol Res. 49:919–928. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Doherty J and Baehrecke EH: Life, death
and autophagy. Nat Cell Biol. 20:1110–1117. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dikic I: Proteasomal and autophagic
degradation systems. Annu Rev Biochem. 86:193–224. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mizushima N and Komatsu M: Autophagy:
Renovation of cells and tissues. Cell. 147:728–741. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Levine B and Kroemer G: Autophagy in the
pathogenesis of disease. Cell. 132:27–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Retnakumar SV and Muller S:
Pharmacological autophagy regulators as therapeutic agents for
inflammatory bowel diseases. Trends Mol Med. 25:516–537. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Long M and McWilliams TG: Monitoring
autophagy in cancer: From bench to bedside. Semin Cancer Biol. Jul
15–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yazdani HO, Huang H and Tsung A:
Autophagy: Dual response in the development of hepatocellular
carcinoma. Cells. 8:E912019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye
WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in
cancer. Chin J Cancer. 36:522017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Elgendy M, Ciro M, Abdel-Aziz AK, Belmonte
G, Dal Zuffo R, Mercurio C, Miracco C, Lanfrancone L, Foiani M and
Minucci S: Beclin 1 restrains tumorigenesis through Mcl-1
destabilization in an autophagy-independent reciprocal manner. Nat
Commun. 5:56372014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Edinger AL and Thompson CB: Defective
autophagy leads to cancer. Cancer Cell. 4:422–424. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shimizu S, Yoshida T, Tsujioka M and
Arakawa S: Autophagic cell death and cancer. Int J Mol Sci.
15:3145–3153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nikoletopoulou V, Markaki M, Palikaras K
and Tavernarakis N: Crosstalk between apoptosis, necrosis and
autophagy. Biochim Biophys Acta. 1833:3448–3459. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gordy C and He YW: The crosstalk between
autophagy and apoptosis: Where does this lead? Protein Cell.
3:17–27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee EF, Smith NA, Soares da Costa TP,
Meftahi N, Yao S, Harris TJ, Tran S, Pettikiriarachchi S, Perugini
MA, Keizer DW, et al: Structural insights into BCL2 pro-survival
protein interactions with the key autophagy regulator BECN1
following phosphorylation by STK4/MST1. Autophagy. 15:785–795.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Levine B, Sinha SC and Kroemer G: Bcl-2
family members: Dual regulators of apoptosis and autophagy.
Autophagy. 4:600–606. 2008. View Article : Google Scholar
|
|
23
|
Wu H, Che X, Zheng Q, Wu A, Pan K, Shao A,
Wu Q, Zhang J and Hong Y: Caspases: A molecular switch node in the
crosstalk between autophagy and apoptosis. Int J Biol Sci.
10:1072–1083. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hou W, Han J, Lu C, Goldstein LA and
Rabinowich H: Autophagic degradation of active caspase-8: A
crosstalk mechanism between autophagy and apoptosis. Autophagy.
6:891–900. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Djavaheri-Mergny M, Maiuri MC and Kroemer
G: Cross talk between apoptosis and autophagy by caspase-mediated
cleavage of Beclin 1. Oncogene. 29:1717–1719. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Salminen A, Kaarniranta K and Kauppinen A:
Beclin 1 interactome controls the crosstalk between apoptosis,
autophagy and inflammasome activation: Impact on the aging process.
Ageing Res Rev. 12:520–534. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qu X, Zou Z, Sun Q, Luby-Phelps K, Cheng
P, Hogan RN, Gilpin C and Levine B: Autophagy gene-dependent
clearance of apoptotic cells during embryonic development. Cell.
128:931–946. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Paquette M, El-Houjeiri L and Pause A:
mTOR pathways in cancer and autophagy. Cancers (Basel). 10:E182018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Boutouja F, Stiehm CM and Platta HW: mTOR:
A cellular regulator interface in health and disease. Cells.
8:E182019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alzahrani AS: PI3K/Akt/mTOR inhibitors in
cancer: At the bench and bedside. Semin Cancer Biol. 59:125–132.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wagle N, Grabiner BC, Van Allen EM, Hodis
E, Jacobus S, Supko JG, Stewart M, Choueiri TM, Gandhi L, Cleary
JM, et al: Activating mTOR mutations in a patient with an
extraordinary response on a phase I trial of everolimus and
pazopanib. Cancer Discov. 4:546–553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jovanović B, Mayer IA, Mayer EL, Abramson
VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver
TM, et al: A randomized phase II neoadjuvant study of cisplatin,
paclitaxel with or without everolimus in patients with stage II/III
triple-negative breast cancer (TNBC): Responses and long-term
outcome correlated with increased frequency of DNA damage response
gene mutations, TNBC subtype, AR status, and Ki67. Clin Cancer Res.
23:4035–4045. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li J, Kim SG and Blenis J: Rapamycin: One
drug, many effects. Cell Metab. 19:373–379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tang J, Li HL, Shen YH, Jin HZ, Yan SK,
Liu RH and Zhang WD: Antitumor activity of extracts and compounds
from the rhizomes of veratrum dahuricum. Phytother Res.
22:1093–1096. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bai F, Liu K, Li H, Wang J, Zhu J, Hao P,
Zhu L, Zhang S, Shan L, Ma W, et al: Veratramine modulates
AP-1-dependent gene transcription by directly binding to
programmable DNA. Nucleic Acids Res. 46:546–557. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tang J, Li HL, Shen YH, Jin HZ, Yan SK,
Liu XH, Zeng HW, Liu RH, Tan YX and Zhang WD: Antitumor and
antiplatelet activity of alkaloids from veratrum dahuricum.
Phytother Res. 24:821–826. 2010.PubMed/NCBI
|
|
38
|
Cong Y, Guo J, Tang Z, Lin S, Zhang Q, Li
J and Cai Z: Metabolism study of veratramine associated with
neurotoxicity by using HPLC-MSn. J Chromatogr Sci. 53:1092–1099.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lyu C, Zhang Y, Zhou W, Zhang S, Kou F,
Wei H, Zhang N and Zuo Z: Gender-dependent pharmacokinetics of
veratramine in rats: In vivo and in vitro evidence. AAPS J.
18:432–444. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gross A, McDonnell JM and Korsmeyer SJ:
BCL-2 family members and the mitochondria in apoptosis. Genes Dev.
13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yorimitsu T and Klionsky DJ: Autophagy:
Molecular machinery for self-eating. Cell Death Differ. 12 (Suppl
2):S1542–S1552. 2005. View Article : Google Scholar
|
|
42
|
Cao Y and Klionsky DJ: Physiological
functions of Atg6/Beclin 1: A unique autophagy-related protein.
Cell Res. 17:839–849. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Porta C, Paglino C and Mosca A: Targeting
PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:642014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xu S, Ge J, Zhang Z and Zhou W: MiR-129
inhibits cell proliferation and metastasis by targeting ETS1 via
PI3K/AKT/mTOR pathway in prostate cancer. Biomed Pharmacother.
96:634–641. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Meng S, Jian Z, Yan X, Li J and Zhang R:
LncRNA SNHG6 inhibits cell proliferation and metastasis by
targeting ETS1 via the PI3K/AKT/mTOR pathway in colorectal cancer.
Mol Med Rep. 20:2541–2548. 2019.PubMed/NCBI
|
|
46
|
Tu Y, Zhu S, Wang J, Burstein E and Jia D:
Natural compounds in the chemoprevention of alcoholic liver
disease. Phytother Res. 33:2192–2212. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Annovazzi L, Caldera V, Mellai M, Riganti
C, Battaglia L, Chirio D, Melcarne A and Schiffer D: The DNA
damage/repair cascade in glioblastoma cell lines after
chemotherapeutic agent treatment. Int J Oncol. 46:2299–2308. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dotan E, Cohen SJ, Starodub AN, Lieu CH,
Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM,
Hecht JR, et al: Phase I/II trial of labetuzumab govitecan
(anti-CEACAM5/SN-38 antibody-drug conjugate) in patients with
refractory or relapsing metastatic colorectal cancer. J Clin Oncol.
35:3338–3346. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li Q, Zhao YL, Long CB, Zhu PF, Liu YP and
Luo XD: Seven new veratramine-type alkaloids with potent analgesic
effect from Veratrum taliense. J Ethnopharmacol. 244:1121372019.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chandler CM and McDougal OM: Medicinal
history of North American. Veratrum. Phytochem Rev. 13:671–694.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Deng S, Shanmugam MK, Kumar AP, Yap CT,
Sethi G and Bishayee A: Targeting autophagy using natural compounds
for cancer prevention and therapy. Cancer. 125:1228–1246. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jung CH, Ro SH, Cao J, Otto NM and Kim DH:
mTOR regulation of autophagy. FEBS Lett. 584:1287–1295. 2010.
View Article : Google Scholar : PubMed/NCBI
|
